PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
90.83
Current ratio of 90.83 while TRAW has zero ratio. Bruce Berkowitz would examine if our liquidity management provides advantages.
90.83
Quick ratio of 90.83 while TRAW has zero ratio. Bruce Berkowitz would examine if our liquidity management provides advantages.
82.43
Cash ratio of 82.43 while TRAW has zero cash ratio. Bruce Berkowitz would examine if our cash management provides competitive advantages.
-7.53
Negative interest coverage while TRAW shows 0.83. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.